From Financial Modeling Prep: 2025-05-30 19:00:00

Guggenheim maintains a “Buy” rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite delays in Itepekimab’s regulatory submissions. The delay has led to an 18.57% decrease in stock price, currently priced at $492.99. Regeneron’s market capitalization is approximately $52.33 billion, with a trading volume of 4,779,116 shares.

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company known for its innovative drug development, particularly in monoclonal antibodies. Despite facing competition, Regeneron collaborates with Sanofi and others to enhance research capabilities. Guggenheim reaffirmed a “Buy” rating for Regeneron on May 30, 2025, with stock priced at $490.24, cautioning due to Itepekimab’s delayed regulatory submissions.

The delay in Itepekimab’s approval poses a challenge for Regeneron, impacting growth potential and stock price. The setback has caused a significant 18.57% decrease in stock price to $492.99. Regeneron’s stock has shown volatility, ranging from $485.04 to $519.78 today, with a peak price of $1,211.20 in the past year, reflecting market fluctuations.

Regeneron’s market capitalization of approximately $52.33 billion highlights its strong presence in the biotechnology industry. Despite recent setbacks, the trading volume of 4,779,116 shares indicates continued investor interest in the company’s future performance. Regeneron’s ability to navigate regulatory challenges and maintain its innovative drug development will be crucial moving forward.



Read more at Financial Modeling Prep:: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Face…